Informed consent
Item
provision of signed and dated written informed consent prior to any study specific procedure.
boolean
C0021430 (UMLS CUI [1])
Non-Small Cell Lung Carcinoma | Non-small cell lung cancer stage IIIB | Non-small cell lung cancer metastatic
Item
patients with histologically- or cytologically-documented nsclc who present with stage iiib/ stage iv disease.
boolean
C0007131 (UMLS CUI [1])
C0278984 (UMLS CUI [2])
C0278987 (UMLS CUI [3])
First line treatment Non-small cell lung cancer metastatic | First line treatment Non-Small Cell Lung Carcinoma Advanced phase | Disease Progression Radiological tumor control | Epidermal growth factor receptor inhibitor Therapeutic procedure | Chemotherapy Regimen
Item
evidence of radiological disease progression following 1st line treatment for advanced/metastatic nsclc with an approved egfr-targeted tki monotherapy without any additional concurrent nsclc treatment. chemotherapy received in the adjuvant setting is permitted.
boolean
C1708063 (UMLS CUI [1,1])
C0278987 (UMLS CUI [1,2])
C1708063 (UMLS CUI [2,1])
C0007131 (UMLS CUI [2,2])
C0205179 (UMLS CUI [2,3])
C0242656 (UMLS CUI [3,1])
C0475190 (UMLS CUI [3,2])
C1443775 (UMLS CUI [4,1])
C0087111 (UMLS CUI [4,2])
C0392920 (UMLS CUI [5])
Chemotherapy Platinum-Based | Pemetrexed-Cisplatin Regimen
Item
patients prescribed platinum based doublet chemotherapy (pemetrexed +
boolean
C3665472 (UMLS CUI [1,1])
C1514162 (UMLS CUI [1,2])
C1882310 (UMLS CUI [2])
Chemotherapy pemetrexed Carboplatin | Second line treatment Non-Small Cell Lung Carcinoma
Item
cisplatin/carboplatin) for 2nd line treatment of nsclc. treatment must have been selected by physician as part of routine standard of care, prior to confirming eligibility for the study. patient must be enrolled into the study within two cycles of beginning treatment. treatment must be given in accordance with local prescribing information.
boolean
C3665472 (UMLS CUI [1,1])
C0210657 (UMLS CUI [1,2])
C0079083 (UMLS CUI [1,3])
C1710038 (UMLS CUI [2,1])
C0007131 (UMLS CUI [2,2])
Neoplasms | EGFR-TKI Sensitizing Mutation | EGFR NP_005219.2:p.L858R | EGFR NP_005219.2:p.L861Q | EGFR NP_005219.2:p.G719X
Item
confirmation prior to enrolment into the study that the tumour harbours the following egfr mutations known to be associated with egfr-targeted tki sensitivity: ex19del, l858r, l861q, and g719x.
boolean
C0027651 (UMLS CUI [1])
C3273083 (UMLS CUI [2])
C3274204 (UMLS CUI [3])
C3274186 (UMLS CUI [4])
C3830332 (UMLS CUI [5])
Neoplasms | EGFR NP_005219.2:p.T790M Gene mutation identification test positive | Disease Progression | First line treatment EGFR-TKI Sensitizing Mutation
Item
patients must have had confirmation that tumour is t790m mutation positive from a biopsy or cytology sample taken after confirmed disease progression on 1st line treatment with an approved egfr-targeted tki.
boolean
C0027651 (UMLS CUI [1])
C3274192 (UMLS CUI [2,1])
C1504360 (UMLS CUI [2,2])
C0242656 (UMLS CUI [3])
C1708063 (UMLS CUI [4,1])
C3273083 (UMLS CUI [4,2])
WHO performance status scale | Deterioration Absent | Life Expectancy
Item
who performance status 0-1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks.
boolean
C1298650 (UMLS CUI [1])
C0868945 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0023671 (UMLS CUI [3])
Therapeutic procedure Following
Item
treatment with any of the following:
boolean
C0087111 (UMLS CUI [1,1])
C0332282 (UMLS CUI [1,2])
Prior Therapy Non-Small Cell Lung Carcinoma Advanced
Item
prior treatment with more than one line of treatment for advanced nsclc.
boolean
C1514463 (UMLS CUI [1,1])
C0007131 (UMLS CUI [1,2])
C0205179 (UMLS CUI [1,3])
major surgery | Vascular Access Device Placement
Item
major surgery (excluding placement of vascular access) within 4 weeks prior to enrolment.
boolean
C0679637 (UMLS CUI [1])
C1519955 (UMLS CUI [2])
Palliative course of radiotherapy | Radiation Field | Bone Marrow
Item
palliative radiotherapy with a limited field of radiation within 1 week prior to enrolment, with the exception of patients receiving radiation to more than 30% of the bone marrow or with a wide field of radiation which must be completed within 4 weeks prior to enrolment.
boolean
C0475092 (UMLS CUI [1])
C1882536 (UMLS CUI [2])
C0005953 (UMLS CUI [3])
Compression of spinal cord | Metastatic malignant neoplasm to brain | Metastatic malignant neoplasm to brain Asymptomatic | Metastatic malignant neoplasm to brain Stable status | Steroids
Item
spinal cord compression or brain metastases unless asymptomatic, stable and not requiring steroids for at least 4 weeks prior to enrolment.
boolean
C0037926 (UMLS CUI [1])
C0220650 (UMLS CUI [2])
C0220650 (UMLS CUI [3,1])
C0231221 (UMLS CUI [3,2])
C0220650 (UMLS CUI [4,1])
C0205360 (UMLS CUI [4,2])
C0038317 (UMLS CUI [5])
Study Subject Participation Status
Item
patients who are known to be entering an alternative interventional clinical study at the time of enrolment into this study will be excluded. however, inclusion in this study does not preclude participation in any other clinical study after enrolment. patients who participate in clinical studies after enrolment into this study will be followed to the extent possible as permitted by the sponsor of that clinical study.
boolean
C2348568 (UMLS CUI [1])
Involvement with Study Staff
Item
involvement in the planning and conduct of the study (applies to astrazeneca staff or staff at the site).
boolean
C1314939 (UMLS CUI [1,1])
C2603343 (UMLS CUI [1,2])
C0851286 (UMLS CUI [1,3])
Compliance behavior Limited
Item
judgment by the physician that the patient should not participate in the study if the patient is unlikely to comply with procedures, restrictions, and requirements.
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])